American Medical Innovation and Investment Act of 2024

12/28/2024, 9:05 AM
Reported (Amended) by the Committee on Ways and Means. H. Rept. 118-958, Part I.
Bill 118 hr 8816, also known as the American Medical Innovation and Investment Act of 2024, is a piece of legislation currently being considered by the US Congress. The main goal of this bill is to promote innovation and investment in the medical field in order to improve healthcare outcomes for Americans.

One key provision of the bill is the establishment of a grant program to support research and development in medical technology and treatments. This program would provide funding to researchers and companies working on cutting-edge medical advancements, with the goal of bringing new and improved treatments to market more quickly.

Additionally, the bill includes measures to streamline the regulatory process for new medical products, making it easier for companies to get their innovations approved by the FDA. This is intended to encourage more investment in medical research and development, ultimately leading to better healthcare options for patients. The American Medical Innovation and Investment Act of 2024 also includes provisions to increase transparency and accountability in the healthcare industry, with the goal of reducing costs and improving access to care for all Americans. This includes measures to promote price transparency for medical services and medications, as well as efforts to combat fraud and abuse in the healthcare system. Overall, this bill aims to foster innovation and investment in the medical field, with the ultimate goal of improving healthcare outcomes for Americans. It is currently being debated in Congress, with supporters arguing that it will lead to better treatments and lower costs, while opponents raise concerns about potential conflicts of interest and the impact on healthcare access for vulnerable populations.
Congress
118

Number
HR - 8816

Introduced on
2024-06-25

# Amendments
0

Sponsors
+5

Variations and Revisions

6/25/2024

Status of Legislation

Bill Introduced
Introduced to House
House to Vote
Introduced to Senate
Senate to Vote

Purpose and Summary

Reported (Amended) by the Committee on Ways and Means. H. Rept. 118-958, Part I.
Bill 118 hr 8816, also known as the American Medical Innovation and Investment Act of 2024, is a piece of legislation currently being considered by the US Congress. The main goal of this bill is to promote innovation and investment in the medical field in order to improve healthcare outcomes for Americans.

One key provision of the bill is the establishment of a grant program to support research and development in medical technology and treatments. This program would provide funding to researchers and companies working on cutting-edge medical advancements, with the goal of bringing new and improved treatments to market more quickly.

Additionally, the bill includes measures to streamline the regulatory process for new medical products, making it easier for companies to get their innovations approved by the FDA. This is intended to encourage more investment in medical research and development, ultimately leading to better healthcare options for patients. The American Medical Innovation and Investment Act of 2024 also includes provisions to increase transparency and accountability in the healthcare industry, with the goal of reducing costs and improving access to care for all Americans. This includes measures to promote price transparency for medical services and medications, as well as efforts to combat fraud and abuse in the healthcare system. Overall, this bill aims to foster innovation and investment in the medical field, with the ultimate goal of improving healthcare outcomes for Americans. It is currently being debated in Congress, with supporters arguing that it will lead to better treatments and lower costs, while opponents raise concerns about potential conflicts of interest and the impact on healthcare access for vulnerable populations.
Alternative Names
Official Title as IntroducedTo amend title XVIII of the Social Security Act to provide for a cognitive impairment detection benefit under the Medicare program, and for other purposes.

Policy Areas
Health

Potential Impact
Advanced technology and technological innovations
Congressional oversight
Government information and archives
Health care costs and insurance
Health care coverage and access
Health promotion and preventive care
Health technology, devices, supplies
Home and outpatient care
Medicare
Neurological disorders
Prescription drugs

Comments

Recent Activity

Latest Action12/27/2024
Reported (Amended) by the Committee on Ways and Means. H. Rept. 118-958, Part I.